Increasing trend of antimicrobial drug-resistance in Pseudomonas aeruginosa causing septicemia

Iranian Journal of Public Health

Volumn 35, Issue 1, 2006, Pages 58-62

  Moniri, R ^a   Mosayebi, Z ^a   Movahedian, A H ^a   Mossavi, Gh A ^a  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Iran; Multi drug resistance; Neonatal septicemia; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMPICILLIN; CARBENICILLIN; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM;

AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; GENDER; GESTATIONAL AGE; GRAM NEGATIVE SEPSIS; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEWBORN; NEWBORN SEPSIS; NONHUMAN; PHENOTYPE; PREVALENCE; PSEUDOMONAS AERUGINOSA; STATISTICAL ANALYSIS; TEACHING HOSPITAL; VENTILATOR;

EID: 33645114766     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Boffi El Amari E, Chamot E, Auckenthaler R, Pechere JC, Van Delden C (2001). Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bactermic isolates. CID, 33(1):1859-64.
2. Loureiro MM, Moraes BA de, Mendonca VLF, Quadra MRR, Pinherio GS, Asensi MD (2002). Pseudomonas aeruginosa: study of antibiotic resistance and molecular typing in hospital infection cases in a neonatal intensive care unit from Rio de Janeiro city, Brazil. Mem Inst Oswaldo Cruz, Rio de Janerio, 97(3): 387-94.
3. Foca M, Jakob K, Whither S, Della Latta P, Factor S, Rubensrein D, Saiman L (2000). Endemic Peudomonas aeruginosa infection in a neonatal intensive care unit. New Engl J Med, 343(10): 695-700.
4. Li XZ, Nikaido H, Poole K (1995). Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. J Antimicrob Agents Chemother, 39: 1948-53.
5. Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M, Daturi R, Romero E, Rossolini GM (2004). Multifocal detection of multi-drug resistant Peudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase in northen Italy. J Clinical Mic, 42(6): 2523-29.
6. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karolwsky JA, Sahm DF (2004). Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother, 48(7): 2431-36.
7. Mosayebi Z, Movahedian AH, Moniri R (2003). Profile of bacterial sepsis in - neonates from Kashan, Iran. J of Infect Dis Antimicrobial Agents, 20(2):97-102.
8. National Committee for Clinical Laboratory Standards (1999). Performance standards for antimicrobial susceptibility testing; Ninth informational supplement. National committee for clinical laboratory - standards, Wayne, Pa.
9. Spencer RC (1996). An 8 year microbe base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. J Antimicrob Chemother, 37(2): 295-301.
10. Sidorenko SV, Gelfand EB, Mamontova OA (1999). Hospital infections caused by Pseudomonas aeruginosa. Anesteziol Reanimatol, 3: 46-54.
11. Tseng YC, Chiu YC, Wang JH, Lin HC, Su BH, Chiu H (2002). Nosocomial blood-stream infection in a neonatal intensive care unit of a medical center: a three-year review. J Microbiol Immunol Infect, 35(3): 168-72.
12. Luzzaro F, Mantengoli E, Perilli M, Lombardi G, Orlandi V, Orsatti A, Amicosante G, Rossolini M, Toniolo A. (2001). Dynamics of a nosocomial outbreak of multi-drug resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol, 39: 1865-70.
13. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, Livemore DM (2000). Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol, 38:1290-92.
14. Wang J, Zhou JY, Yu YS (2005). Study on the drug resistance and beta-lactamases of Pseudomonas aeroginosa. Zhonghua Jie He He Hu Xi Za Zhi, 28 (4):258-62.
15. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B (2005). Carbapenem resistance mechanism in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS, 113(3): 187-96.
16. Zavascki AP, Cruz RP, Goldani LZ (2005). Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect, 59(2): 96-101.
17. Michea-Hamzehpour M, Pechere JC, Marchou B, Auckenthaler R (1986). Combination therapy: a way to limit emergence of resistance? Am J Med, 80: 138.
18. Michea-Hamzehpour M, Auckenthaler R, Regamey P, Pechere JC (1987). Resistance occurr ing after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother, 31:1803.
19. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999). Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother, 43:1379.
20. Wisplinghoff H, Bischoff T, Tallent SM, et al. (2004). Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis, 39: 309.